LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 196 filers reported holding LIGAND PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.16 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $6,142 | +555.5% | 86 | +561.5% | 0.00% | – |
| Q2 2023 | $937 | -2.0% | 13 | 0.0% | 0.00% | – |
| Q1 2023 | $956 | -4.4% | 13 | -18.8% | 0.00% | – |
| Q3 2022 | $1,000 | -99.7% | 16 | -99.6% | 0.00% | -100.0% |
| Q3 2019 | $384,000 | -15.4% | 3,853 | -3.2% | 0.03% | -16.1% |
| Q2 2019 | $454,000 | -98.0% | 3,979 | +2110.6% | 0.03% | +1450.0% |
| Q1 2019 | $22,628,000 | -21.0% | 180 | -14.7% | 0.00% | 0.0% |
| Q4 2018 | $28,633,000 | -54.2% | 211 | -7.5% | 0.00% | -60.0% |
| Q3 2018 | $62,584,000 | -89.0% | 228 | -91.7% | 0.01% | -88.9% |
| Q2 2018 | $568,474,000 | +32.8% | 2,744 | +5.9% | 0.04% | +28.6% |
| Q1 2018 | $428,095,000 | +43.4% | 2,592 | +18.9% | 0.04% | +40.0% |
| Q4 2017 | $298,507,000 | +3.3% | 2,180 | +2.7% | 0.02% | +4.2% |
| Q3 2017 | $288,910,000 | +17.3% | 2,122 | +4.6% | 0.02% | +9.1% |
| Q2 2017 | $246,321,000 | – | 2,029 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 2,626,160 | $138,136,000 | 24.17% |
| KNOTT DAVID M | 1,292,566 | $67,988,972,000 | 13.87% |
| GROW Partners, LLC | 200,000 | $10,520,000 | 6.41% |
| Opaleye Management Inc. | 90,000 | $4,860,000,000 | 3.82% |
| OBERWEIS ASSET MANAGEMENT INC/ | 213,317 | $11,220,000 | 2.72% |
| First Light Asset Management, LLC | 60,242 | $3,169,000 | 2.69% |
| Timpani Capital Management LLC | 98,956 | $5,205,000 | 2.59% |
| Iguana Healthcare Management, LLC | 75,000 | $3,945,000 | 2.25% |
| Eventide Asset Management | 134,400 | $7,069,000 | 2.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 215,223 | $11,321,000 | 2.16% |